Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

AYTU vs AQST: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

AYTU Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 6–4 Matrix Metrics)

AYTU Overall Winner 6-Pillar Tally: AYTU 6 – 0 AQST Matrix Metrics: AYTU 6 – 4 AQST

As of Nov 16, 2026, AYTU BioPharma, Inc. (AYTU) is the stronger overall head-to-head candidate over Aquestive Therapeutics, Inc. (AQST) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AYTU carries a Unified Composite Score of 48.9/100 (HOLD) at $1.81 (9.2x Forward P/E, -14.4% operating margin), whereas AQST carries 59.4/100 (HOLD) at $3.77 (N/M Forward P/E, -114.1% operating margin).

  • Composite vs. Pillar Nuance: While AQST currently prints a higher short-term Unified Composite Score (59.4/100 HOLD vs. AYTU 48.9/100 HOLD), AYTU captures the overall institutional head-to-head verdict (6–4 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (-14.4% vs. -114.1% operating margin) and revenue trajectory (+6.4% vs. -41.0% YoY).
  • Technical & Structure Timing Caution: AYTU is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.7); meanwhile AQST is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 43.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AYTU vs AQST
AYTU NASDAQ Head-to-Head Winner
AYTU BioPharma, Inc. Common Stock
Pharmaceutical Preparations
$1.81
+1.69% 1D
Market Cap $19.6M
TTM Revenue $58M
Forward P/E 9.2x
Beta / 30D Vol 0.65β · 35% Vol
Unified Composite Score
48.9 / 100 HOLD
Tech 49.0 Fund 53.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -7.8%), weak momentum, RSI 38
RSI-14: 37.7 · SMA20: $1.89 · SMA50: $2.00
AQST NASDAQ
Aquestive Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$3.77
-3.45% 1D
Market Cap $448.7M
TTM Revenue $49M
Forward P/E N/M
Beta / 30D Vol 0.87β · 56% Vol
Unified Composite Score
59.4 / 100 HOLD
Tech 69.0 Fund 66.0 Flow 71.0 Mom 54.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -7.9%), weak momentum, RSI 44
RSI-14: 43.7 · SMA20: $3.85 · SMA50: $4.34

6-Pillar Scorecard Institutional Category Breakdown (AYTU 6 – 0 AQST)

Columns: Metric · AYTU · AQST
1. Valuation Multiples AYTU
Forward P/E 9.2x N/M
Trailing P/E 9.2x N/M
PEG Ratio N/M N/M
EV / Revenue 0.3x 8.5x
2. Growth & Scale AYTU
Revenue Growth (YoY) +6.4% -41.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $58M $49M
Market Cap $19.6M $448.7M
3. Profitability & Quality AYTU
Gross Margin 64.0% 65.3%
Operating Margin -14.4% -114.1%
Net Profit Margin -24.8% -162.3%
Return on Equity (ROE) -52.5% 0.0%
4. Balance Sheet & Cash Flow AYTU
Cash Generation (TTM) -$1.4M -$41M
Cash Flow Margin -2.4% -83.3%
Net Cash / Leverage $4.9M Net Cash $32M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning AYTU
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) 61.9% (40th %ile)
Put/Call OI Skew N/A 0.38x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat AYTU
OpEx & R&D Intensity 78.4% of Rev ($45M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Drug Manufacturers - Specialty & Generic Operator Drug Manufacturers - Specialty & Generic Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AYTU (6) vs AQST (4)
Institutional Metric AYTU AQST Criterion Row Edge
Market Capitalization
Scale
$19.6M $448.7M Larger Scale AQST
Trailing P/E Ratio
Valuation
9.2x N/M Lower Multiple AYTU
Forward P/E Ratio
Valuation
9.2x N/M Lower Multiple AYTU
Revenue Growth (YoY)
Growth
+6.4% -41.0% Higher Growth AYTU
Operating Margin (TTM)
Profitability
-14.4% -114.1% Higher Margin AYTU
Net Profit Margin
Profitability
-24.8% -162.3% Higher Margin AYTU
Return on Equity (ROE)
Capital Efficiency
-52.5% 0.0% Higher ROE AQST
52-Week Range Position
Momentum
5% ($2–$3) 22% ($3–$7) Stronger Trend AQST
Beta / 30D Volatility
Risk Regime
0.65β · 35% Vol 0.87β · 56% Vol Lower Realized Risk AYTU
Unified Institutional Score
Composite Signal
48.9 / 100 (HOLD) 59.4 / 100 (HOLD) Higher Composite AQST
Trailing 12M Revenue (USD)
Operating Scale
$58M $49M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
64.0% 65.3% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.3x EV/Rev N/M PEG · 8.5x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$1.4M ($4.9M Net Cash) -$41M ($32M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon AQST +11.14 pp
AYTU: -11.27% · AQST: -0.13%
3M Horizon AQST +10.69 pp
AYTU: -23.31% · AQST: -12.62%
6M Horizon AQST +5.1 pp
AYTU: -13.81% · AQST: -8.71%
1Y Horizon AYTU +16.63 pp
AYTU: -12.14% · AQST: -28.77%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period AYTU Revenue AQST Revenue AYTU Op. Margin AQST Op. Margin Margin Leader
FY2019 $10M $50M -230.1% -100.1% AQST
FY2020 $30M $50M -76.5% -93.6% AYTU
FY2021 $70M $50M -89.7% -68.2% AQST
FY2022 $100M $50M -113.7% -88.2% AQST
FY2023 $110M $50M -15.9% -29.9% AYTU
FY2024 $70M $60M -2.4% -53.5% AYTU
FY2025 $70M $40M -11.8% -159.5% AYTU
FY2026 $60M N/A -14.4% N/A AYTU

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AYTU UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AYTU Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
AQST BREAKDOWN
57d in phase · OBV DISTRIBUTION
Current IV 61.9%
IV Percentile 40th %ile
Put/Call OI Skew 0.38x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact AQST Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AYTU Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $19.6M market capitalization and -14.4% operating margin.
OpEx & R&D Reinvestment 78.4% of Rev ($45M)
90D Engineering Disclosures 0 Published
AQST Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $448.7M market capitalization and -114.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ AYTU vs AQST Key Questions & Quantitative Answers

As of Nov 16, 2026, AYTU BioPharma, Inc. (AYTU) is the stronger overall head-to-head candidate over Aquestive Therapeutics, Inc. (AQST) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AYTU carries a Unified Composite Score of 48.9/100 (HOLD) at $1.81 (9.2x Forward P/E, -14.4% operating margin), whereas AQST carries 59.4/100 (HOLD) at $3.77 (N/M Forward P/E, -114.1% operating margin). Composite vs. Pillar Nuance: While AQST currently prints a higher short-term Unified Composite Score (59.4/100 HOLD vs. AYTU 48.9/100 HOLD), AYTU captures the overall institutional head-to-head verdict (6–4 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (-14.4% vs. -114.1% operating margin) and revenue trajectory (+6.4% vs. -41.0% YoY). Technical & Structure Timing Caution: AYTU is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.7); meanwhile AQST is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 43.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

AYTU leads the Growth & Scale pillar: AYTU posts +6.4% YoY revenue growth and +0.0% YoY earnings growth on $58M TTM revenue (64.0% gross margin, -14.4% operating margin), compared with AQST at -41.0% YoY revenue growth and +0.0% YoY earnings growth on $49M TTM revenue (65.3% gross margin, -114.1% operating margin). Across the 8-period historical trajectory (FY2019 to FY2026), AYTU cumulative revenue shifted +500.0% while AQST shifted -20.0%. In operating R&D and SG&A reinvestment, AYTU deploys 78.4% of Rev ($45M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for AQST.

AYTU screens cheaper on headline valuation multiples. AYTU trades at 9.2x Forward P/E, 9.2x Trailing P/E, N/M PEG, and 0.3x EV/Revenue (-2.4% FCF margin), whereas AQST trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 8.5x EV/Revenue (-83.3% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AYTU (-52.5% ROE) versus AQST (0.0% ROE) capital efficiency.

In options market volatility and institutional positioning, AYTU carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.65β · 35% Vol realized risk). By comparison, AQST carries 61.9% implied volatility (40th %ile, Balanced (25th–60th %ile)), a 0.38x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.87β · 56% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.